RELMADA THERAPEUTICS, INC. — Director's Dealing 2021

Jan 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-01-22

Reporting Person: Kelly Paul Edward (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-22	Common Stock	M	4085	$3.24	Acquired	151380	Direct
2021-01-22	Common Stock	S	1800	$3543	Disposed	149580	Direct
2021-01-22	Common Stock	S	300	$36.18	Disposed	149280	Direct
2021-01-25	Common Stock	S	1300	$35.27	Disposed	147980	Direct
2021-01-26	Common Stock	S	685	$35.16	Disposed	147295	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-22	Options to purchase common stock	$3.24	M	4085	Disposed	2027-10-20	Common Stock (3400)	Direct

Footnotes

F1: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b51 trading plan adopted by the reporting person on December 22, 2020.

F2: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3: Sales prices range from $35.04 to $35.98 per share, inclusive.

F4: Sales prices range from $36.06 to $36.37 per share, inclusive.

F5: Sales prices range from $35.00 to $35.51 per share, inclusive.

F6: Sales prices range from $35.00 to $35.75 per share, inclusive.

F7: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

F8: Not applicable.